Dyne Therapeutics Completes Enrollment for Key DM1 Trial, Sets Q1 2027 Data Target
DYN has more than doubled off its 52-week low of $8.06.
Summary
Dyne Therapeutics announced the full enrollment of the registrational expansion cohort for its z-basivarsen trial in myotonic dystrophy type 1 (DM1), a critical step towards potential accelerated FDA approval and a planned 2028 launch.
Key Events · Product Development and Regulatory · DYN
-
Trial Enrollment Complete
Dyne Therapeutics has fully enrolled the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial for z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1), with 71 participants.
-
Key Data & Regulatory Timelines Set
Topline data from the ACHIEVE REC is expected in Q1 2027, supporting a potential Biologics License Application (BLA) submission for U.S. Accelerated Approval in Q3 2027.
-
Anticipated Product Launch
The company anticipates a potential U.S. launch of z-basivarsen in the first half of 2028, contingent on FDA Priority Review and approval.
Analysis · DYN · Life Sciences
This 8-K marks a significant de-risking event for Dyne's lead DM1 program, z-basivarsen. Completing enrollment in the registrational cohort moves the drug closer to market, providing investors with clear timelines for upcoming data readouts, regulatory submissions, and a potential launch. Given DM1 has no approved disease-modifying treatments, this progress is highly important for the company's future revenue potential and addresses a critical unmet medical need.
At the time of this filing, DYN was trading at $18.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.